Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: High Grade Glioma
Interventions: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy; Procedure · Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions: PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more

Conditions: Anxiety, Infertility, Female
Interventions: In-person yoga for fertility group, Online yoga for fertility group, In person discussion only group; Behavioral
Lead sponsor: Fertility Centers of Illinois; Other
Eligibility: 24 Years to 42 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more

Conditions: Learning, Humans, Consolidation, Sleep
Interventions: Associative inference, Category learning, Sleep; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 35 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: RO7446603, Aflibercept, Faricimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 70
States / cities: Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: Birmingham, Alabama • Anchorage, Alaska • Duarte, California + 36 more

Conditions: Breast Cancer
Interventions: Dasatinib and Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pain
Interventions: Interactive decision support tool; Other
Lead sponsor: Shared Decision Making Resources; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Georgetown, Maine

Conditions: Solid Tumor
Interventions: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Bendamustine, Ofatumumab, Carboplatin, Etoposide, CT Scan, PET Scan, Stem Cell Transplant (STC); Drug · Procedure · Genetic
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Energy Deficiency Due to Short-term Fasting
Interventions: r-metHuLeptin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: Low-load resistance training with blood flow restriction; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Interventions: Yoga, Yoga Questionnaire, Symptom Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Interventions: Patient Navigation, Standard Medication Counseling (SMC); Behavioral · Other
Lead sponsor: Jerry Cochran; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Melanoma
Interventions: IN10018, Cobimetinib, Atezolizumab; Drug · Biological
Lead sponsor: InxMed (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Heart, Heart Failure, Ejection Fraction, Left Ventricular Ejection Fraction, Left Ventricular Ejection Fraction Less Then or Equal to 50percent
Interventions: PLAX EF Manual vs. Automatic Measurement; Device
Lead sponsor: EchoNous Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Attention Deficit/Hyperactivity Disorder(ADHD), Alcohol Use
Interventions: Ecological Momentary Assessment for ADHD and Substance Use - Intervention Group, Ecological Momentary Assessment for ADHD & Substance Use - Control Group; Device
Lead sponsor: Traci Kennedy; Other
Eligibility: 18 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Myelodysplastic Syndromes
Interventions: Oral Azacitidine, Placebo for Oral Azacitidine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Miami, Florida • Tamarac, Florida • East Syracuse, New York + 3 more

Conditions: Solid Tumors
Interventions: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions: SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Breast Cancer
Interventions: interactive 3D tool, BREAST-Q Reconstruction Module, DQI, Ottawa Decision Regret Scale; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

STARLITE for Unresectable High-Grade Gliomas

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Stress and Fertility: How to Lower Stress When Trying to Conceive

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Human Learning of New Structured Information Across Time and Sleep

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Pharmacokinetics of Leptin Administration During Fasting

Low-load Resistance Training With Blood Flow Restriction in People With Parkinson's Disease

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

Healthy Opioid Prescription Engagement

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Kosmos PLAX EF Pivotal Study

Smartphone-based Intervention for Young Adults With ADHD

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery